Alpha Tau Medical has delivered a week that splits neatly into two stories: an earnings print that moved the stock higher on the day, and a subsequent sell-off that has wiped nearly 14% off the price — with short sellers accelerating into the weakness.
The post-earnings price action is the sharpest signal. DRTS closed at $8.93 on June 2, down 7.6% on the day and down 13.9% on the week. That's a striking reversal for a stock that gained roughly 4% over the prior month and had analysts queuing up with fresh conviction. The June 2 earnings release itself landed without a recorded 1-day reaction in the historical data, but the broader trajectory is clear: the stock has given back meaningful ground in the days immediately following the event.
Short sellers have moved decisively into that weakness. SI has jumped 76% over the past month to reach 1.94% of free float — still a modest absolute level, but the rate of change is what matters here. Week-on-week, short interest rose 42%. That's not a small drift; it's a directional positioning call. Borrow availability has tightened sharply in response, dropping from 194% a week ago to 47% now — meaning there are roughly half as many shares available to borrow as are currently borrowed. That's a tight lending market by any measure, though well above the 52-week low of 2.2%. Cost to borrow has eased modestly from its mid-May peak above 11% to 8.6%, suggesting the scramble for borrows has cooled slightly even as short interest continues to climb.
Options positioning tells a calmer story than the price action might suggest. The put/call ratio is running at 0.15 — elevated versus its 20-day average of 0.14 by about 1.3 standard deviations, but still deeply call-heavy in absolute terms. This is a stock where options traders have overwhelmingly favored upside exposure, and that hasn't flipped despite the sell-off. The ORTEX short score has climbed to 58.3, its highest reading of the past two weeks, reflecting the combination of rising short interest and tightening availability.
The Street remains largely constructive, but there's a clear divide in conviction. Barclays initiated last week with Overweight at a $15 target — the most significant recent endorsement given the firm's standing. HC Wainwright has reiterated Buy at $15 as recently as June 2. Ladenburg Thalmann lifted its target to $14 in May. Piper Sandler is the lone Neutral voice, with a $8 target that sits almost exactly where the stock is trading now — a position that looks prescient after this week's decline. The mean price target of $15.25 implies roughly 71% upside from current levels, though that gap reflects as much clinical uncertainty as it does valuation conviction. The bull case rests on Alpha DaRT's platform data in glioblastoma and squamous cell carcinoma, with pivotal trial topline data expected in late 2026. Bears flag the absence of commercial revenue, ongoing cash burn, and a competitive oncology landscape.
Factor scores add nuance to the Street's enthusiasm. EPS momentum rankings are genuinely exceptional — 96th percentile over 30 days and 88th percentile over 90 days — reflecting analysts revising estimates upward. The analyst recommendation divergence score ranks in the 92nd percentile, confirming the unusual spread between bulls and the lone neutral. But short score rank (18th percentile) and days-to-cover rank (16th percentile) suggest the short community's growing interest is still not yet extreme in a historical context, even after this week's acceleration. The next catalyst is the Q3 earnings event currently flagged for August 11 — and what to watch between now and then is whether the tightening borrow market and rising short interest stabilize or continue to build as the pivotal trial data window approaches.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
